-
Journal of Experimental Pharmacology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies
Review
(1195) Views (1557) Full article downloads
Authors: Chun-Hsiang Wang, Yuchi Hwang, Eugene Lin
Published Date July 2010
Volume 2010:2 Pages 73 - 82
DOI: http://dx.doi.org/10.2147/JEP.S8655
Chun-Hsiang Wang1, Yuchi Hwang2, Eugene Lin2
1Department of Hepatogastroenterology, Tainan Municipal Hospital, Tainan, Taiwan; 2Vita Genomics, Inc., Taipei, Taiwan
Abstract: Chronic hepatitis C (CHC) is a liver disease characterized by infection with the hepatitis C virus (HCV) persisting for more than six months. Patients with CHC often stop pursuing the pegylated interferon (peg-IFN) and ribavirin (RBV) treatment because of the high cost and associated adverse effects. Therefore, it is highly desirable, both clinically and economically, to establish the determinants of response to distinguish responders from nonresponders, and to predict the possible outcomes of the peg-IFN and RBV treatments. The aim of this study was to review recent data on the pharmacogenomics of the drug efficacy of IFN in CHC patients. Single nucleotide polymorphisms (SNPs) can be used to understand the relationship between genetic inheritance and IFN therapeutic response. In the recent advent of scientific research, the genome-wide association study (GWAS), which is an alternative to the candidate-gene approach, is widely utilized to examine hundreds of thousands of SNPs by high-throughput genotyping technologies. In addition to the candidate-gene approach, the GWAS approach has recently been employed to study the determinants of HCV’s response to therapy. Several recent findings have demonstrated that some SNPs in the interleukin 28B gene are closely associated with IFN responsiveness. These results promise to lead to mechanistic findings related to IFN responsiveness in this disease, and will probably have major contributions for individualized medicine and therapeutic decision making.
Keywords: chronic hepatitis C, genome-wide association study, interferon, pharmacogenomics, ribavirin, single nucleotide polymorphisms
Other articles by Dr Eugene Lin
A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesityAssociation study of a brain-derived neurotrophic factor polymorphism and short-term antidepressant response in major depressive disorders
Identification of significant genes in genomics using Bayesian variable selection methods
Modeling short-term antidepressant responsiveness with artificial neural networks
Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms
Pilot study of an association between a common variant in the non-muscle myosin heavy chain 9 (MYH9) gene and type 2 diabetic nephropathy in a Taiwanese population
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




